Instituto Dannemann Siemsen de Estudos Jurídicos e Técnicos
This article has been written by Natália Barzilai and Gisela de Lamare de Paiva Coelho
As a result of the massive backlog of two hundred and forty-four thousand patents applications as of May, 2017, the Brazilian Patent and Trademark Office (BPTO) has been studying multiple measures to continually reduce the already famous tardiness of its examinations. The BPTO has come up with some controversial ideas.
Successfully, the BPTO has created categories in order to speed up its process, the first one being the “Green Patents”, reducing by 90% the processing time regarding the analysis of environment related innovations. After such a positive outcome, in June, 22, the BPTO extended this project to innovations from the Science and Technology Institutions (STI). Although it is still a temporary strategy limited to a certain number of “STI Patent” applications, the BPTO seeks to reduce from the average time from 10,8 years to 10 months as it is already the case with “Green Patents”.
Another conservative approach to reduce the backlog created by the reduce number of technical examiners, is to join forces with ANVISA (Brazilian Health Agency). As required by the Brazilian IP Law, the BPTO must send all pharmaceutical patents to the Health Agency to be analyzed and check out if there is no forbidden substance in it. Only after obtaining prior approval the BPTO’s technical exam can start. Having such a relevant role in the process of the analysis, the BPTO has proposed ANVISA to send its examiners to the BPTO facilities. Such small measure can help optimize the proceedings not only because the BPTO has an automatic system but because it also prevents losing time between Agencies’ transfers. In addition, the BPTO and ANVISA have established two guidelines in 2017 to fasten ANVISA’s analysis. Now granting of prior approval is based only on the presence of forbidden substance – not on the patentability of the innovation as it used to be. These guidelines not only shorten the analysis period but also provide more legal security as the Health Agency is obliged to grant the approval based only in public health requirement.
Besides those measures, facing the original source of the backlog, the BPTO is studying the possibility of implementing the successful method applied by the Japan Patent Office (JPO). As presented by Takuya Yasui in December, 2017, Japan successfully tackled its backlog by adopting two measures. First, by sub-contracting all preliminary activities, such as research before technical decisions. Today JPO has 10 companies providing its research and, even though they are private companies, supervisors are often retired JPO’s examiners. Second, hiring temporary examiners for 5-year periods which can be renewed for 5 more. With such changes, the time until the exam was reduced from 2,4 years in 2008 to 10,4 months in 2014.
Regarding the most controversial proposals, the BPTO has issued Resolution nº 193 seeking to expedite the examination of Brazilian patent applications under the PCT. In this Resolution, the BPTO has regulated that it will not perform a search of its own and will only incorporate the search already performed by an “office of reference”, meaning, International Searching Authorities (ISA) and International Preliminary Examining Authorities (IPEA).
The BPTO also started a public consultation for a proposal establishing that patent applications filed or with the national phase initiated up to the date of publication of the future regulation, will be granted 90 days, following a notice of admissibility, to decide whether they want to opt or not for a simplified patent application procedure, provided that they meet certain requirements and are not the subject of third-party observations (also called pre-grant oppositions). Patent applications for pharmaceutical products and processes are, in principle, excluded from this simplified procedure, potentially for political reasons and because of the scrutiny of ANVISA regarding these patents.
As reported in a previous publication at Dannemann Siemsen News, according to the proposed simplified procedure, the patent applications to which it applies will be automatically allowed without substantive examination, provided that a few requirements are met:
- Certificates of addition, divisional applications and, as above-mentioned applications covering pharmaceutical products and processes are not eligible;
- The filing of the patent application or request for entry into the national phase (in the case of PCT applications) should have occurred before the publication date of the proposed regulation;
- The application has been published or the early publication requested up to thirty days from the date of publication of the future regulation;
- Examination of the patent application should have been requested within 30 days following the publication date of the future regulation;
- Annuities payments must be in order; and
- No official actions regarding patentability have been published.
Our general advice would be to remove patent applications related to important inventions from the simplified procedure due to the following reasons: (i) the future patents are more likely to face validity challenges; (ii) BPTO’s delay would be compensated somehow since our IP Law currently guarantees a minimum of 10-year patent term from granting date; and (iii) it is possible to put an application to a fast-track examination in case of unauthorized exploitation or through a writ of mandamus.
In particular applicants having a large number of pending patent applications in Brazil should begin to chart a strategy in relation to their portfolio in view of possible new regulations. Meanwhile, we are hoping for the best.
 Ahlert, I. B., Murari Calazans, S. “Brazilian Government considers adopting simplified procedure for granting patents without substantive examination”, 1st december 2017, http://www.dannemann.com.br/dsbim/Biblioteca_Detalhe.aspx?&ID=1094&pp=1&pi=1